Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology

NCT07161453 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

500

Enrollment

OTHER

Sponsor class

Conditions

Gastric / Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: SOX plus PD-1 inhibitor
DRUG: PD-1 / PD-L1 monoclonal antibody
DRUG: SOX Chemotherapy
DRUG: Tegafur-Ugotex or Capecitabine

Sponsor

Liaoning Cancer Hospital & Institute